The PMPRB protects and informs Canadians by ensuring that
the prices of patented medicines sold in Canada are not excessive and by
reporting on pharmaceutical trends.
The Biologics in Canada series examines Canadian and international trends in the sales, cost, use, and pricing of biologics as of the end of 2018.
Find out more…
This edition of the report analyzes the market for inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) combination inhalers used in the treatment of asthma.
Horizon scanning report that features a selection of new medicines in the late stages of clinical evaluation that may have a significant impact on future clinical practice and drug spending in Canada.
This is the fourth edition of the PMPRB’s Meds Entry Watch report, which explores the market entry of new medicines in Canada and other countries.
The PMPRB is consulting with its stakeholders on changes to
its non-binding guidelines (the “Guidelines”), as contemplated by subsection 96(4) of the Patent Act.
Find out more